$0.8085
+0.09
(+12.31%)▲
Revenue is up for the last 2 quarters, 18.99M → 19.28M (in $), with an average increase of 1.5% per quarter
Netprofit is up for the last 2 quarters, -59.42M → -47.11M (in $), with an average increase of 26.1% per quarter
In the last 1 year, Novo Nordisk A/s has given 288.9% return, outperforming this stock by 374.2%
In the last 3 years, Novo Nordisk A/s has given 451.5% return, outperforming this stock by 549.4%
15.93%
Downside
Day's Volatility :15.93%
Upside
0.0%
13.58%
Downside
52 Weeks Volatility :87.83%
Upside
85.91%
Period | Adc Therapeutics Sa | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -64.0% | -1.4% | 0.0% |
6 Months | -63.64% | 2.2% | 2.0% |
1 Year | -84.55% | 6.0% | 5.3% |
3 Years | -97.86% | 26.3% | 19.9% |
Market Capitalization | 98.4M |
Book Value | - $0.1 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -2.31 |
Wall Street Target Price | 8.17 |
Profit Margin | -98.33% |
Operating Margin TTM | -56.94% |
Return On Assets TTM | -12.77% |
Return On Equity TTM | -339.67% |
Revenue TTM | 184.4M |
Revenue Per Share TTM | 2.3 |
Quarterly Revenue Growth YOY | 11.5% |
Gross Profit TTM | 35.1M |
EBITDA | -103.9M |
Diluted Eps TTM | -2.31 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.9 |
EPS Estimate Next Year | -2.61 |
EPS Estimate Current Quarter | -0.46 |
EPS Estimate Next Quarter | -0.7 |
What analysts predicted
Upside of 910.51%
Sell
Neutral
Buy
Adc Therapeutics Sa is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Adc Therapeutics Sa | -44.19% | -63.64% | -84.55% | -97.86% | -97.57% |
![]() Moderna, Inc. | -10.67% | -32.6% | -16.46% | 43.93% | 437.58% |
![]() Regeneron Pharmaceuticals, Inc. | -0.66% | 0.54% | 20.22% | 43.69% | 111.47% |
![]() Novo Nordisk A/s | 2.15% | 146.19% | 299.73% | 451.49% | 690.33% |
![]() Seagen, Inc. | 6.95% | 7.06% | 57.98% | 15.54% | 167.56% |
![]() Vertex Pharmaceuticals Incorporated | -0.15% | 13.31% | 26.28% | 30.33% | 91.37% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Adc Therapeutics Sa | NA | NA | NA | -1.9 | -3.4 | -0.13 | 0.0 | -0.1 |
![]() Moderna, Inc. | 34.92 | 34.92 | 0.0 | -3.42 | 0.07 | 0.01 | 0.0 | 44.49 |
![]() Regeneron Pharmaceuticals, Inc. | 21.9 | 21.9 | 9.01 | 41.82 | 0.19 | 0.1 | 0.0 | 225.94 |
![]() Novo Nordisk A/s | 42.86 | 42.86 | 2.03 | 1.66 | 0.82 | 0.22 | 0.01 | 2.52 |
![]() Seagen, Inc. | NA | NA | 18.53 | -3.52 | -0.26 | -0.13 | 0.0 | 13.96 |
![]() Vertex Pharmaceuticals Incorporated | 27.48 | 27.48 | 0.41 | 14.71 | 0.25 | 0.16 | 0.0 | 60.01 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Adc Therapeutics Sa | Buy | $98.4M | -97.57% | NA | -98.33% |
![]() Moderna, Inc. | Buy | $38.1B | 437.58% | 34.92 | 11.33% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $89.4B | 111.47% | 21.9 | 33.93% |
![]() Novo Nordisk A/s | Buy | $409.3B | 690.33% | 42.86 | 33.4% |
![]() Seagen, Inc. | Hold | $38.7B | 167.56% | NA | -33.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $90.2B | 91.37% | 27.48 | 35.4% |
Redmile Group, LLC
Citadel Advisors Llc
Prosight Management, LP
JPMorgan Chase & Co
Goldman Sachs Group Inc
Sio Capital Management, LLC
Adc Therapeutics Sa’s price-to-earnings ratio stands at None
Read Moreadc therapeutics is a biotechnology company located in lausanne, vaud, switzerland.
Organization | Adc Therapeutics Sa |
Employees | 317 |
CEO | Dr. Ameet Mallik M.B.A., M.S. |
Industry | Health Technology |
Virtus Dividend, Interest & Premium Strategy Fund
$0.81
+12.31%
Primis Financial Corp
$0.81
+12.31%
Diversified Healthcare Trust
$0.81
+12.31%
Calamp Corp.
$0.81
+12.31%
Orthofix Medical Inc
$0.81
+12.31%
Nextgen Healthcare, Inc.
$0.81
+12.31%
Spdr Ftse International Gove
$0.81
+12.31%
Teucrim Soybean Fund
$0.81
+12.31%
Farmers National Banc Corp
$0.81
+12.31%